Background. Treatment of patients with juvenile idiopathic arthritis (JIA) is one of the most
METHODS

Study design
A monocenter observational comparative study was conducted.
Eligibility criteria Inclusion criteria:
• the age under 18 years old; • confirmed diagnosis of JIA according to ILAR criteria (International League of Associations for Rheumatology), including active chronic poly-or oligoarticular disease;
• the presence of more than one swollen joint and/or more than one painful joints with limited mobility within at least 6 months, and/or active uveitis; • administration of NSAIDs and glucocorticoids at stable doses for at least 1 month prior to treatment with adalimumab; • no evidence of tuberculosis (latent tuberculosis was excluded by means of Mantoux reaction and computed tomography of the chest); • negative pregnancy test (for all girls over the age of 14 years old).
Non-inclusion criteria:
• any concomitant disease or deviation from normal laboratory values, which could affect the patient's participation in the study, according to the clinical evaluation of the researcher;
• any of the contraindications listed in the instructions for medical use of the drug, including: -congestive heart failure, conditions with immunodeficiency; -current infectious disease or the need for vaccination with live attenuated vaccine; -severe uncontrolled systemic manifestations and/or the presence of biological evidence of macrophage activation syndrome; -abnormal liver function with liver aminotransferases activity more than two-fold exceeding the normal reference range;
• social or other reasons that may prevent the performance of regular medical checkups.
Terms of study conduction
The study was conducted in the period from August 2008 to August 2014 on the basis of a specialized rheumatology department of the Scientific Center of Children's Health (Moscow).
Patients were sequentially enrolled.
Methods of reporting outcomes
All patients underwent a complete clinical laboratory and instrumental examination by the standards care in JA adopted in the Russian Federation. The following parameters were evaluated:
• activity of articular syndrome (number of swollen joints, joints with pain at palpation and movement, joints with impaired function, duration of the morning stiffness);
• functional activity of patients (according to the data of a special questionnaire Childhood Health Assessment Questionnaire, CHAQ); functional activity was considered expressed at CHAQ> 1,6, moderate -at the values from 0.64 to 1.6, the minimal -from 0.14 to 0.63;
• a global assessment of disease activity by physician and subjective assessment of well-being by patient or his parent (by 100 mm visual analog scale, VAS); the value of less than 5 points was considered as normal. Evaluation of clinical activity of the disease was carried out prior to treatment, after 1, 3, 6 months and then once per year.
Laboratory indicators of disease activity, erythrocyte sedimentation rate (ESR) and serum concentration of C-reactive protein (CRP), were measured before treatment and, consequently, at each visit.
Treatment efficacy was evaluated by pediatric criteria of the American College of Rheumatology (ACRpedi) and C. Wallace remission criteria.
The effectiveness by ACRpedi was determined based on the overall patient's (parents') assessment of the state of health, the global assessment of the disease activity by a doctor by 100 mm VAS (points), functional capacity according to the CHAQ questionnaire, number of joints with active arthritis, number of joints with impaired function, the value of the ESR or CRP. The effectiveness by ACRpedi30/50/70 means improving at least by 30/50/70% for at least 3 of the 6 criteria with possible deterioration by 30% for not more than one indicator compared to the baseline value [2] .
C. Wallace remission criteria of the disease include the absence of joints with active arthritis, absence of fever, rash, serositis, organomegaly, generalized lymphadenopathy, normal values of ESR and CRP, the absence of the disease activity according to the physician's judgement (by VAS), duration of morning stiffness is less than 15 min [2] .
Medical intervention
The study does not imply an experimental medical treatment and all treatments were carried out in accordance with the standards/ guidelines for treatment of juvenile arthritis, adopted in Russian Federation [1] .
Treatment outcomes
The target treatment efficacy indicator was the achievement of the inactive stage of the disease/remission with the use of the study drugs for at least three consecutive months in 1, 3, 6, 9 and 12 months, then once per year.
Evaluation of the safety of therapy was performed by means of recording the number of adverse events (AEs), which was considered as any adverse change in the medical condition of the patient who received the drug, regardless of the causal relationship with the treatment. The number of adverse events was calculated by the formula: Table 2 ).
The general well-being according to the patient or his parents was significantly worse in the main group. According to the physician's assessment of the disease activity in patients of both groups, it did not differ significantly and corresponded to the moderate and a high degree. It should be noted that in both groups patients or parents assessed well-being worse than a doctor (see Table 2 ).
Thus, prior to treatment with adalimumab and methotrexate all children with JIA had active articular syndrome, functional insufficiency of varying degrees of severity, increased laboratory markers of activity (erythrocyte sedimentation rate, serum CRP), poor well-being and high activity of the disease according to patients (or their parents) and the doctor.
Dosage and administration of the drugs and follow-up duration
Adalimumab was administered at a dose of 40 mg (one syringe regardless of the weight and age of the child), once in two weeks, subcutaneously, in the abdominal region or the outer surface of the hand, after treatment of the skin with an alcohol swab. Dose and mode of adalimumab administration remained unchanged throughout the period of observation.
All children of the main group (n = 214) had received at least six injections of adalimumab (3 months of therapy). Within 3 months 214 patients were observed, 6 months -191 (89%), 9 months -166 (76%), 1 year -157 (73%), 1.5 years -131 (61%), 2 years -108 (51%), 2.5 years -70 (33%), 3 years -51 (24%), 4 years -17 (8%), 5 years -9 (4%) children. Mean duration of follow-up was 1.8 (0.9, 2.5) years. 54 (25%) patients were excluded from the study; 5 children have not reached the intermediate point "6 months", 29 -"1 year" point, 65 -"2 years" point, 113 -"3 years" point, 147 -"4 years" point, 152 -"5 years" point.
Methotrexate was administered at a dose of 15 (15; 20) mg/m 2 per week by subcutaneous or intramuscular injections, for at least 3 months. Within 6 months 150 (75%) were observed, 1 year -122 (61%), 2 years -112 (56%), 3 years -107 (53.5%), 4 years -100 (50%) patients. Mean duration of follow-up was 2.9 (0.6; 5) years. 102 (51%) patients were excluded from the study (reasons for exclusion from the study are provided in Section "Survival").
Background therapy
Background therapy and doses of immunosuppressive drugs are provided in Table 3 . Adalimumab was assigned against the background of immunosuppressive treatment to 204 (95.3%) patients. Characteristics of prior treatment Prior to this study, all patients underwent anti-rheumatic therapy in various modes. 67 (31.3%) and 32 (16.0%) children of the main and control groups, respectively, were assigned oral prednisolone at a dose of 0.1 to 2 mg/kg per day at a place of residence in the territorial medical institutions; intra-articular injections of glucocorticoids were performed with a frequency of 1-12 injections per year in 102 (47.4%) and 88 (44%) patients, methylprednisolone pulse therapy at a dose of 5-30 mg/kg of body weight per administration was assigned to 14 (6.5%) and 6 (3%) patients in the two groups, respectively. All children received NSAIDs.
All patients of the main group before the study received immunosuppressive drugs: methotrexate -197 (92%), cyclosporin -94 (44%), leflunomide -14 (6.5%), hydroxychloroquine -27 (12.6%), sulfasalazine -70 (32.7%), cyclophosphamide -8 (3.7%) azathioprine -5 (2.3%). In the group of comparison, methotrexate was the first immunosuppressant in 163 (81.5%) patients, the second or the third in 37 (18.5%); 6 (3%) children received cyclosporin, 30 (15%) -sulfasalazine, 1 (0.5%) -cyclophosphamide. Duration of anti-rheumatic therapy prior to the initiation of the study was 3.3 (2; 6.8) and 1.5 (0.6, 4) years in the main group and the group of comparison, respectively (p <0.001). 
Key findings
Articular syndrome After 1 month (0.08 years) after the first injection of adalimumab the number of painful joints had decreased by 5 times, the number of swollen joints and joints with active arthritis -two-fold, the number of joints with impaired function -1.3 times as compared with the baseline value (Fig. 1) . The duration of morning stiffness decreased by 6 times and it became significantly lower than in children treated with methotrexate. In 157 (52.1%) patients joint pain was completely resolved, 71 (33%) had no joints with determined active arthritis. Children in the group of comparison within this follow-up period did not show the reliable dynamics of the values of clinical parameters of disease activity. In 6 (3%) patients who received methotrexate, the number of painful joints and joints with impaired function had decreased and in 14 (7%) patients articular syndrome had spread.
After 3 months, the value of markers of disease activity in the main group were still lower than in patients of the group of comparison. In patients treated with adalimumab, the median of the number of painful, swollen joints and joints with active arthritis has become equal to 0. The number of joints with impaired function decreased by 4 times. Morning stiffness was resolved in 188 (87.8%), articular syndrome -in 135 (63%) patients. In 54 (25.2%) patients articular syndrome transformed into oligoarthritis type of duration. In patients treated with methotrexate, significant dynamics of values of clinical parameters of disease activity at 3 months (0.25 years) have not been observed. The tendency towards the reduction of the number of painful joints, swollen joints and joints with dysfunction was observed (see Fig. 1 ).
After 6 months (0.5 years) in the main group, the median of the number of painful, swollen joints, and joints with active arthritis and dysfunction corresponded to 0. In the group of comparison for the first time during the observation period, significant decrease in all indicators of the articular syndrome activity was recorded. The median of the number of swollen and painful joints and joints with active arthritis as well as in the study group became equal to 0, the median number of joints with impaired function decreased by 2.5 times; duration of morning stiffness was reduced by 2 times. The difference between the two groups on these indicators at 6 months (0.5 years) of follow-up was leveled (see Fig. 1 ). Articular syndrome was resolved in 138/191 (72%) and 79/150 (53%), morning stiffness -in 175/191 (91.6%) and 55/150 (37%), the range of motion was fully recovered in 107/191 (56%) and 36/150 (24%) patients of the main group and control group, respectively.
After one year remission of articular syndrome was registered in 128/157 (81.5%) and 79/122 (65%); the full range of motions in the joints -in 99/157 (63%) and 40/122 (33%) patients of main group and control group, respectively. In 21/157 (13.4%) and 43/122 (35%) patients of both groups articular syndrome recurred as oligoarthritis in 8/157 (5.1%) and 6/122 (4.9%) in accordance with the type of arthritis.
After two years of remission of articular syndrome persisted in 90/108 (83%) and 79/112 (70.5%) patients treated with adalimumab and methotrexate, respectively. Active articular syndrome by the type of oligoarthritis remained in 15/108 (13.9%) and 27/112 (24%), on the type of polyarthritis -in 3/108 (2.8%) and 6/112 (5.3%) patients from both groups. However, articular syndrome was still significantly more active in patients treated with methotrexate. In 70/108 (64.8%) and 87/112 (78%) children in both groups there was no joints with motion restriction.
After three years remission of the articular syndrome was recorded in 47/51 (92%) and 79/107 (74%), complete restoration of the function in the joints -in 38/51 (74.5%) and 40/107 (38%) out of patients of both groups, remaining in the study. The joints with active arthritis were detected in 3/51 (5.9%) and 28/107 (26%) children of the main group and the group of comparison.
After four years remission of articular syndrome was observed in 14/17 (82%) and 79/100 (79%); the full range of motion in the joints -in 12/17 (70.6%) and 40/100 (40%) patients treated with adalimumab and methotrexate, respectively. In 3/17 (17.6%) and 21/100 (21%) children of the main and control group after four years articular syndrome continued to recur.
To the 5 th year, the median number of painful joints corresponded to 0 in both groups; the number of swollen joints, joints with active arthritis, with impaired function -1 (0;1) in the main group and 0 (0;0) in the group of comparison (see Figure 1) . Articular syndrome was resolved in the 4/9 and 79/98 (81%) patients, the range of motions in the joints was fully recovered in the 4/9 and 41/98 (42%) children who were treated with adalimumab and methotrexate, respectively.
Laboratory markers of disease activity
Dynamics of laboratory markers of activity (ESR, CRP) in the main group and the comparison group were as well controversial. One month after the first adalimumab injection ESR value declined compared to the baseline, as well as in relation to the values in the group of comparison and conformed to the reference values in 151/214 (71%) patients. Serum CRP value in patients treated with adalimumab also had declined compared to the baseline values as well as the values of the group of comparison and conformed to the reference values in 168/214 (78.5%) patients. In the group of children treated with methotrexate, the dynamics of laboratory parameters was unremarkable. ESR values and serum CRP concentration corresponded to the reference values in 150/214 (70%) and 90/200 (45%) patients of the main and control group, respectively (Fig. 2, 3) .
After 3 months in patients of the main group laboratory parameters continued to decline. ESR values and serum CRP concentration normalized in 198/214 (92.5%) and 141/214 (65.8%) patients, respectively. In the comparison group, ESR values returned to normal in 90/200 (45%) patients, however, the median of ESR values was still significantly higher than that of a study group (see Fig. 2 ). No significant dynamics of serum CRP levels in patients treated with methotrexate was observed, and they were as well significantly higher than in the main group (see Fig. 3 ). Serum CRP concentrations of normalized in 58/200 (29%) patients. respectively. Median CRP and ESR values matched normal values in both groups. However, ESR and CRP serum levels in patients treated with adalimumab were significantly lower than in patients treated with methotrexate (see Fig. 2 and 3) .
After 1 year of laboratory markers of the disease activity ESR and CRP corresponded to normal values in 148/157 (94%) and 102/150 (68%) patients in both groups. A moderate increase in erythrocyte sedimentation rate persisted in 8/157 (5.1%) and 39/150 (26%), serum CRP level -in 9/157 (5.7%) and 48/150 (32%) children treated with adalimumab and methotrexate, respectively. After 2 years, ESR and CRP serum levels decreased in both groups, but were lower in patients treated with adalimumab. Normal laboratory parameters were reported in 100/108 (92.6%) and 79/112 (70.5%) children of the main group and the group of comparison, respectively.
To the 3 rd year follow-up, ESR and serum CRP levels corresponded to the normal reference range values in 46/51 (90%) and 89/107 (83%) patients treated with adalimumab and methotrexate. In the group of comparison ESR greater than 15 mm/h was recorded in 17/107 (16%) patients, increased serum concentrations of CRP -in 16/107 (15%) patients. Statistically significant differences between groups were not observed (see Fig. 2 and 3) .
After 4 years, increased ESR and CRP serum concentration persisted in 2/17 patients of the main group. In the comparison group accelerated ESR was observed in 8/100 (8%), increased CRP serum concentrations -in 16/100 (16%) patients. Maximum ESR was 37 and 55 mm/h, serum CRP level -20.11 and 53 mg/L in patients treated with adalimumab and methotrexate, respectively.
After 5 years, increased erythrocyte sedimentation rate was observed in 12/98 (12%) patients receiving methotrexate (max 48 mm/h), serum CRP -in 2/9 patients of the main group (max 9.75 mg/L), and 19/98 (19%) children of the group of comparison (max 53 mg/L).
The functional ability according to the CHAQ questionnaire Impact of the study drugs on the functional ability of patients was also significantly different. Within 1 month after the first injection of adalimumab index of functional impairment by the CHAQ questionnaire decreased in comparison with the baseline value as well as in comparison with the control group (Fig. 4) . There was no dynamics of this indicator observed in the group of patients treated with methotrexate.
Full functional activity was recorded in 88/214 (41%) and 16/200 (8%) patients of the main group and control group, respectively. The number of patients with severe functional impairment after 1 month of treatment in the main group decreased by 4.7 times and was 14/214 (6.5%), while prior to treatment it was 66/214 (30.8%).
By the 3 rd month, the index of functional impairment in patients treated with adalimumab continued to decline and was lower than in the control group. In patients treated with methotrexate, the dynamics of this indicator was not observed (see Fig. 4 ).
In 111/214 (51.8%) patients treated with adalimumab, functional ability was fully restored; functional impairment remained at the same level in children who received methotrexate. Severe functional impairment was recorded in 7/214 (3.2%) and 55/200 (28%), moderate or minimal -in 96/214 (44.8%) and 159/200 (79.5%) patients of the main group and control group, respectively. After 6 months in children of the main group functional activity by CHAQ index continued to improve significantly. The dynamics of this indicator was observed in patients treated with methotrexate. In patients treated with adalimumab functional index of impairment was still significantly lower than in the group of comparison.
Full functional activity according to the CHAQ questionnaire was recorded in 120/191 (62.8%) and 70/150 (46.7%), moderate or minimal functional impairment -in 65/191 (34%) and 62/150 (41.3%), severe functional impairment -in 6/191 (3.1%) and 18/150 (12%) patients of the main group and control group, respectively. After 1 year, the index of functional impairment according to CHAQ questionnaire in the observed patients did not differ significantly. In 4/157 (2.6%) and 45/122 (37%) patients treated with adalimumab and methotrexate given value was above 1.
After 2 years functional activity according to CHAQ questionnaire was fully recovered in 85/108 (78.7%) and 70/112 (62.5%) patients of both groups. 4/108 (3.7%) and 13/112 (19%) patients had moderate functional impairment (CHAQ from 0.64 to 1.6), 19/108 (17.6%) and 19/112 (17%) had minimal impairment (CHAQ index from 0.14 to 0.63). Severely impaired functional ability remained in 4/108 (3.7%) and 10/112 (8.9%) patients of the main group and group of control.
After 3 years in 40/51 (78%) and 77/107 (72%) patients treated with adalimumab and methotrexate, respectively, the functional status according to CHAQ questionnaire was not impaired or minimally reduced; moderate functional impairment was registered in 2/51 (3.9%) and 20/107 (18.7%) children in both groups, and severe functional impairment in 10/107 (9.3%) patients of the group of comparison.
After 4 years functional ability according to CHAQ questionnaire in 14/17 patients in the main group was not impaired, in 2/17 -moderately impaired, and in 1 child minimal impairment was reported. In 70/100 (70%) patients in the group of comparison CHAQ index was equal to 0, in 13/100 (13%) it was above 1 point (suggesting a moderate and severe functional impairment); in 17/100 (17%) CHAQ index was within the range of 0.14-0.63, which corresponded to the minimum functional impairment.
After 5 years, the functional ability according to the CHAQ questionnaire was not impaired in 7/9 patients of the main group and 69/98 (70%) patients in the control group. In 2/9 and 7/98 (7%) children who received adalimumab and methotrexate, CHAQ index corresponded to the minimum functional impairment (0.14-0.63). Severe functional impairment (CHAQ index> 1.6) was registered in 8/98 (8%) patients from the comparison group.
Activity of the disease by the visual analog scale according to the doctor and subjective evaluation of the well-being according to the patient or his parents
The above-described pattern was also observed for the indicators of subjective health assessment according to the patient or his/her parents, and the disease activity according to the doctor.
Within 1 month after the first injection of adalimumab health assessment according to the child or his/her parents and disease activity according to the physician by VAS had decreased compared with the baseline values [Me (25%; 75%) -73 (63; 87.75); 60.5 (50; 73,75) and 33 (12; 48); 30 (9; 40) points according to the patient's opinion/his or her parents and doctor before and after 1 month, respectively] and similar parameters in the control group [68 (50; 80) and 60 (46; 80); 68 (50; 80) and 61.5 (46; 80) points, respectively; P <0.0001]. In the group of patients treated with methotrexate, change of the values of the above parameters did not occur.
After 3 months the disease activity according by VAS according to the doctor in the main group had decreased even more significantly [60.5 (50; 73,75) and 9.5 (0; 23,75) points before and after 3 months; p <0.0001] and did not exceed 5 points (corresponding to the normal reference range) in 87/214 (40.6%) patients; well-being by VAS according to the patient or his/her parents was significantly improved [73 (63; 87,75) and 12 (0; 27) points before and after 3 months; P <0.0001]. In the group of comparison indicators of the disease activity and health status according to the physician and parents did not change from the baseline and were significantly higher than in the main group [12 (0; 27) and 9.5 (0; 23,75) points -in the main group; 55.5 (41; 67) and 65 (50; 80) points -in the control group, p <0.0001].
After 6 months the disease activity by VAS according to the doctor continued to decline in the main group [60.5 (50; 73,75); 5 (0; 18) points before and after 6 months p <0.0001] and for the first time statistically significant decrease was observed in the control group [60 (46; 80) and 23 (12, 38) points before and after 6 months, respectively; P <0.0001]. This indicator in patients treated with adalimumab was significantly lower than in patients treated with methotrexate [5 (0; 18) ; 23 (12; 38) points, respectively; P <0.0001]. The general state of health of patients by VAS according to children and/or their parents was also improved in both groups [73 (63; 87.75); 6 (0 20.5) points -before and after 6 months in the study group; p <0.0001; 68 (50; 80); 32 (21, 46) points -before and after 6 months in the control group, p <0.0001]. However, patients treated with adalimumab, rated their health status and well-being significantly better than children receiving methotrexate.
After 1 After 2 years, overall health status according to patient or parent's assessment had improved significantly in both groups of patients. At the same time the median of the above index in the main group was lower than in the comparison group [0 (0; 10.25) 5 (0; 24.75); p = 0.0010]. According to the doctor, the disease activity by VAS was low in both groups; the median corresponded to 0.
After 3 years the activity of the disease according to the physician and overall health status assessment according to the patient or his/her parents by VAS was evaluated as normal (<5 points) in 34/51 (66.7%) and 75/107 (70%) patients of the main and control groups, respectively. Median of the parameters for both groups was statistically equal to 0. Significant differences were observed between the groups.
After 4 years good well-being according to the patient or his/her parents by VAS was recorded in 11/17 and 75/100 (75%) patients of the main group and the group of comparison [0 (0; 9) and 0 (0; 0), respectively]. According to the doctor, the disease remission (<5 points) took place in 12/17 and 77/100 (77%) patients treated with adalimumab and methotrexate, respectively. Activity of the disease persisted in 5/17 and 23/100 (23%) patients in the main and control group.
After 5 years of follow-up the median of the subjective general health assessment according to the patient (or his/her parent) by VAS remained equal to 0 in both groups. Remission of the disease was observed, according to the doctor, in 4/9 and 80/98 (82%) patients of the main group and the group of comparison.
Evaluation of treatment effectiveness according to ACRpedi criteria
After 1 month 87/54/25% of patients treated with adalimumab met the improvement criteria according to ACRpedi30/50/70, which was significantly higher (p <0.001) than in patients treated with methotrexate (28/19/6%; Fig. 5 ). After 3 months ACRpedi30/50/70 response in the main group was 91/85/65% and it was still significantly higher (p <0.001) than in the comparison group (37/23/7%). After 6 months, in patients treated with methotrexate effect of therapy was registered for the first time, accounting for 63/57/47% by ACRpedi30/50/70 criteria, but it was lower (p <0.001) than in the main group (93/89/76%). After 9 and 12 months, the level of response according to ACRpedi criteria in patients receiving adalimumab, was still higher than during treatment with methotrexate: 95/92/82; 72/69/58% (p <0.001) and 93/92/84; 78/73/67% (p <0.001), respectively. After 2 years of treatment the difference between groups was reduced, 96/94/85 and 85/80/74% of patients (p = 0.017) met the improvement ACRpedi30/50/70 criteria. After 3 years, the difference in response was not detected: the response rate was 94/92/88 and 89/88/81% (P = 0.650) in patients treated with adalimumab and methotrexate, respectively. Over the next 2 years of follow-up efficiency of the study drugs according to ACRpedi criteria did not differ (see. Note (hereafter in Fig. 6, 7) . "Group 1" -main group, "Group 2" -group of comparison.
Disease remission according to the C. Wallace criteria
Terms and frequency of achieving inactive disease/remission and its duration in the two groups were significantly different throughout the observation period. In 1 and 3 months from the initiation of treatment in the main group stage of inactive disease was reported in 32 (15%) and 71 (33%) patients, respectively. In the comparison group, no patients met the assessed criteria (Fig. 6 ). After 6 months the stage of the inactive disease/remission was registered in 82 (43%) patients treated with adalimumab, it was 4 times as high as this value in patients treated with methotrexate (9%). In 9 months a significant difference between the groups remained and it was 81 (49%) and 24 (19%), respectively. In 1 year the incidence of remission in the group of comparison showed two-fold increase and was 38%, it did not differ from the incidence in the main group (47%). After 2 years the difference between the two groups was completely leveled, stage of the inactive disease/ remission was reported in 56 (52%) and 60 (54%) patients (p = 0.698), respectively. In the next 3 years of observation, the study groups did not differ by the above index. Adalimumab induced stage of inactive disease/remission more quickly compared to methotrexate -5 (3; 8) and 12 (6; 18) months, respectively (P <0.001), and its duration was significantly longer than in the comparison group -21 (14; 26) and 12 (8; 15) months, respectively (p <0.001; see Figure 6 ). 
Additional findings
Effect of treatment with adalimumab and methotrexate at the dose of 15 mg/m 2 per week on the background therapy in patients with juvenile idiopathic arthritis without systemic manifestations Adalimumab and methotrexate have NSAID-effect and hormone-sparing effect, but it is more pronounced for TNF-α inhibitor. High therapeutic effectiveness of adalimumab allowed to discontinue NSAIDs in 184 (86%) patients after 1 month, 212 (99%) -in 1 year of observation; to avoid prednisolone appointment de novo and increase of its daily dose in all patients; to reduce the dose of oral corticosteroids in 4 (20%) patients, and withhold their administration in one child; to discontinue intraarticular injections and intravenous infusion of glucocorticoids to all patients. Methotrexate exerts less pronounced anti-inflammatory and hormone-sparing effect properties, predetermined by its weaker therapeutic efficacy. After 1 month NSAIDs were discontinued in 60 (30%) after 1 year -98 (49%) patients; prednisolone dose was reduced in 5 (28%), intraarticular and intravenous corticosteroids were discontinued in 176 (88%) and 100%, respectively.
"Survival" of treatment with adalimumab and methotrexate at a dose of 15 mg/m 2 per week in patients with juvenile idiopathic arthritis without systemic manifestations The cumulative effect of the "survival" of therapy with adalimumab was significantly higher than for the treatment with methotrexate throughout the observation period and in 6 months it accounted for 95 and 77%, in 1 year -84 and 60%, after 2 years -73 and 54%, in 3 years -62 and 53%, in 4 years -62 and 50%, after 5 years -62 and 49% in the main group and the control group, respectively (Figure 7 ). Adalimumab and methotrexate were discontinued in 25.1% and 51% of patients (see Fig. 7) .
During the first 6 months 19/215 (8.3%) and 50/200 (25%) patients discontinued their participation in the study, during the 1 st year -29/215 (13%) and 78/200 (39%), during the 2 nd year of observations -13/215 (6%) and 10/200 (5%) of patients receiving adalimumab and methotrexate (see Fig. 7 ). The main reasons for the methotrexate discontinuation included primary (21%) and partial (11%) ineffectiveness; for adalimumab -organizational problems (7%), AEs (5.6%), primary lack of response to treatment (5.6%). 
